We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+15.57%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$759M
AUM Growth
+$1.33M
Cap. Flow
-$40.4M
Cap. Flow %
-5.32%
Top 10 Hldgs %
61.45%
Holding
63
New
9
Increased
18
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$23.3M
2
IRON icon
Disc Medicine
IRON
+$15.3M
3
CATX icon
Perspective Therapeutics
CATX
+$14.7M
4
MGTX icon
MeiraGTx Holdings
MGTX
+$13.2M
5
QTTB icon
Q32 Bio
QTTB
+$4.95M

Top Sells

Rank Stock Value
1
HROW icon
Harrow
HROW
+$47.2M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$20.1M
3
CGON icon
CG Oncology
CGON
+$17.9M
4
ALKS icon
Alkermes
ALKS
+$13.7M
5
OCUL icon
Ocular Therapeutix
OCUL
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
26
Relmada Therapeutics
RLMD
$482M
$6.51M 0.86%
935,000
– –
CGON icon
27
CG Oncology
CGON
$7B
$6.42M 0.85%
94,800
-315,200
-77% -$17.9M
JBIO
28
Jade Biosciences
JBIO
$1.35B
$6.01M 0.79%
427,608
– –
OCUL icon
29
Ocular Therapeutix
OCUL
$2.38B
$5.08M 0.67%
600,000
-995,000
-62% -$9.48M
ASRT
30
DELISTED
Assertio
ASRT
$5.06M 0.67%
265,707
-19,293
-7% -$237K
EDIT icon
31
Editas Medicine
EDIT
$507M
$4.76M 0.63%
+1,926,997
New +$4.08M
STRO icon
32
Sutro Biopharma
STRO
$353M
$4.75M 0.63%
190,671
– –
DERM icon
33
Journey Medical
DERM
$213M
$4.5M 0.59%
960,000
-15,000
-2% -$116K
VYGR icon
34
Voyager Therapeutics
VYGR
$213M
$4.44M 0.58%
1,150,000
-46,904
-4% -$185K
TRVI icon
35
Trevi Therapeutics
TRVI
$2.56B
$4.12M 0.54%
345,100
– –
TECX
36
Tectonic Therapeutic
TECX
$717M
$3.8M 0.5%
123,000
-91,747
-43% -$2.26M
CABA icon
37
Cabaletta Bio
CABA
$573M
$3.71M 0.49%
1,380,000
+480,000
+53% +$1.33M
BDSX icon
38
Biodesix
BDSX
$300M
$3.45M 0.45%
+238,047
New +$2.95M
RCKT icon
39
Rocket Pharmaceuticals
RCKT
$397M
$3.42M 0.45%
955,000
– –
ZNTL icon
40
Zentalis Pharmaceuticals
ZNTL
$367M
$3.31M 0.44%
1,412,656
+11,750
+0.8% +$30.3K
NTLA icon
41
Intellia Therapeutics
NTLA
$1.84B
$3.14M 0.41%
+245,000
New +$3.12M
FBIO icon
42
Fortress Biotech
FBIO
$93.4M
$2.91M 0.38%
1,042,000
-48,000
-4% -$163K
IRD
43
Opus Genetics
IRD
$320M
$2.25M 0.3%
1,120,000
– –
RIGL icon
44
Rigel Pharmaceuticals
RIGL
$875M
$1.89M 0.25%
70,000
– –
AVIR icon
45
Atea Pharmaceuticals
AVIR
$437M
$1.74M 0.23%
322,600
+142,785
+79% +$656K
LYEL icon
46
Lyell Immunopharma
LYEL
$358M
$1.59M 0.21%
+79,097
New +$1.85M
ENTA icon
47
Enanta Pharmaceuticals
ENTA
$402M
$1.58M 0.21%
125,000
+50,000
+67% +$670K
NXTC icon
48
NextCure
NXTC
$27.6M
$1.51M 0.2%
+141,181
New +$1.72M
FDMT icon
49
4D Molecular Therapeutics
FDMT
$824M
$1.05M 0.14%
+112,291
New +$977K
CATX icon
50
CALL
Perspective Therapeutics
CATX
$363M
$834K 0.11%
+200,000
New +$845K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2026 Portfolio in Review

As of Q1 2026, Opaleye Management held 63 positions worth $759M, up 0.18% from $758M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Opaleye Management withdrew a net $40.4M in Q1 2026, closing 9 positions and reducing 13 holdings. Its most notable exit was Alkermes, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Editas Medicine worth $4.76M.

  • Opaleye Management's largest Q1 2026 buy was Editas Medicine: 1,926,997 shares worth $4.76M.
  • Opaleye Management added most to UroGen Pharma in Q1 2026, an estimated $23.3M increase.
  • Opaleye Management's biggest Q1 2026 reduction was Harrow, cutting an estimated $47.2M.
  • Opaleye Management fully exited Alkermes in Q1 2026, selling an estimated $13.7M.
  • Opaleye Management's ten largest holdings make up 61% of its $759M portfolio in Q1 2026.
  • Opaleye Management opened 9 new positions and closed 9 in Q1 2026.
  • Opaleye Management's portfolio value rose 0.18% quarter-over-quarter to $759M.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.